secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-09-17T12:30:40+00:00
Accession:  0001493152-26-043053
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir reports peer-reviewed study: Telomir-Zn restores retinal structure/function in AMD model
--------------------------------------------------------------------------------

- Telomir-Zn restored visual function and retinal structure after 14 days oral treatment in zebrafish AMD model; published in Int. J. Mol. Sci. 2026, 27(18), 8265.
- Treatment reduced mitochondrial oxidative stress and restored thickness across multiple retinal layers including outer/inner nuclear, outer plexiform, and ganglion cell layers.
- Telomir-Zn inhibited Fe²⁺-dependent Jumonji C histone demethylases across KDM2/KDM5/KDM6 families, strongest against KDM5B (IC50 63 nM).
- Dose-dependent increase in relative telomeric DNA content toward wild-type profile and restoration of DNA methylation at aging-associated CpG loci.
- Clinical priority remains oncology: FDA-cleared Phase 1/2 trial of Telomir-Zn in advanced or metastatic triple-negative breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226043053/0001493152-26-043053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226043053/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-043053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer